Shylaja Prashanth, MD
Rheumatology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location · University Healthcare Alliance · 334 clinicians in this group
Looking this up.
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Prashanth’s office at (408) 357-1425 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A100963 · Current
Licensed to practise in California · since 2007 · expires 2027-05-31 · University of Health Sciences, Vijayawada, Kakatiya Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$288,116
Medicare paid this office $288,116 for 365 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 76 | $141,843 | None |
| Return visit (30+ min) | 254 | $60,128 | $113 |
| New patient visit (45+ min) | 96 | $14,418 | $150 |
| Short return visit (20+ min) | 54 | $5,725 | $85 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 152 | $3,003 | $15 |
See all 12 services
| Injection, denosumab, 1 mg | 76 | $141,843 | None |
| Return visit (30+ min) | 254 | $60,128 | $113 |
| New patient visit (45+ min) | 96 | $14,418 | $150 |
| Short return visit (20+ min) | 54 | $5,725 | $85 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 152 | $3,003 | $15 |
| Long return visit (40+ min) | 15 | $2,933 | $140 |
| Injection of drug or substance under skin or into muscle | 88 | $2,761 | $14 |
| Aspiration and/or injection of fluid from large joint | 16 | $1,163 | $61 |
| Influenza vaccine split virus, preservative free | 14 | $1,145 | $82 |
| Aspiration and/or injection of fluid from small joint | 13 | $628 | $45 |
| Administration of influenza virus vaccine | 15 | $573 | $38 |
| Injection, methylprednisolone acetate, 1 mg | 29 | $143 | None |
Who their Medicare patients are
365 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 12% · Women 80% · Also on Medicaid 8% · Health risk score 1.14. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 67% · Coronary heart disease 26% · Diabetes 24% · Chronic kidney disease 18% · Cancer 16% · Depression 16% · Heart failure 12% · Atrial fibrillation 12% · COPD 11% · Stroke 8% · Dementia 5%.
The office billed $1,296,781, Medicare allowed $371,236 and paid $288,116; for 18,875 services of 30 kinds; $193,529 of it was for drugs given in the office and $94,587 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 365 | 18,875 | 75 | 1.14 | $1,296,781 | $288,116 |
| 2023 | 329 | 20,752 | 75 | 1.10 | $1,177,798 | $261,609 |
| 2022 | 339 | 42,920 | 75 | 1.11 | $1,925,173 | $428,728 |
| 2021 | 331 | 49,565 | 75 | 1.26 | $2,391,952 | $541,693 |
| 2020 | 264 | 35,029 | 75 | 1.38 | $1,936,329 | $437,541 |
| 2019 | 240 | 18,271 | 74 | 1.26 | $949,362 | $225,785 |
| 2018 | 144 | 3,312 | 75 | 1.36 | $212,579 | $57,020 |
| 2017 | 224 | 5,936 | 74 | 1.41 | $704,828 | $388,560 |
| 2016 | 260 | 10,107 | 73 | 1.43 | $1,237,810 | $661,372 |
| 2015 | 181 | 3,721 | 72 | 1.21 | $462,730 | $243,911 |
| 2014 | 44 | 128 | 72 | 1.23 | $18,422 | $9,083 |
| 2013 | 82 | 305 | 72 | 1.74 | $33,184 | $18,019 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Injection, denosumab, 1 mg | 47 | $77,221 | None |
| Return visit (30+ min) | 214 | $52,978 | $112 |
| New patient visit (45+ min) | 93 | $13,531 | $145 |
| Short return visit (20+ min) | 46 | $4,976 | $80 |
| Injection of drug or substance under skin or into muscle | 66 | $1,935 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 20 | $1,580 | $63 |
| Aspiration and/or injection of fluid from large joint | 14 | $1,163 | $65 |
| Influenza vaccine split virus, preservative free | 16 | $1,151 | $72 |
| Injection into tendon or ligament | 11 | $747 | $50 |
| Administration of influenza virus vaccine | 17 | $628 | $37 |
| Injection, methylprednisolone acetate, 40 mg | 24 | $230 | None |
| Injection, methylprednisolone acetate, 20 mg | 15 | $97 | None |
2022: 17 services
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 17 | $90,276 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $61,694 | None |
| Return visit (30+ min) | 198 | $56,772 | $114 |
| Injection, denosumab, 1 mg | 29 | $43,064 | None |
| New patient visit (45+ min) | 81 | $11,427 | $141 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 54 | $6,545 | $69 |
| Short return visit (20+ min) | 60 | $6,242 | $83 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $2,813 | $141 |
| Injection of drug or substance under skin or into muscle | 58 | $2,329 | $14 |
| Long return visit (40+ min) | 12 | $2,113 | $163 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $1,693 | $81 |
| Aspiration and/or injection of fluid from large joint | 18 | $1,357 | $68 |
| New patient visit (30+ min) | 11 | $1,177 | $107 |
| Injection, zoledronic acid, 1 mg | 26 | $614 | None |
| Administration of influenza virus vaccine | 11 | $410 | $37 |
| Injection, methylprednisolone acetate, 40 mg | 26 | $189 | None |
| Injection, methylprednisolone acetate, 20 mg | 14 | $49 | None |
2021: 19 services
| Injection, tocilizumab, 1 mg | 16 | $110,227 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 16 | $93,963 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 16 | $78,337 | None |
| Return visit (30+ min) | 155 | $43,905 | $123 |
| Injection, denosumab, 1 mg | 29 | $42,417 | None |
| Injection, golimumab, 1 mg, for intravenous use | 15 | $38,467 | None |
| Long return visit (40+ min) | 58 | $13,150 | $160 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 73 | $9,227 | $72 |
| New patient visit (45+ min) | 59 | $8,844 | $150 |
| New patient visit (60+ min) | 40 | $7,790 | $195 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | $3,254 | $108 |
| Short return visit (20+ min) | 29 | $2,625 | $85 |
| Telephone medical discussion with physician, 11-20 minutes | 26 | $2,357 | $81 |
| Aspiration and/or injection of fluid from large joint | 18 | $1,974 | $68 |
| Injection of drug or substance under skin or into muscle | 56 | $1,599 | $13 |
| Influenza vaccine split virus, preservative free | 23 | $1,497 | $65 |
| Injection, zoledronic acid, 1 mg | 23 | $836 | None |
| Administration of influenza virus vaccine | 23 | $503 | $22 |
| Injection, methylprednisolone acetate, 40 mg | 40 | $288 | None |
2020: 19 services
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 14 | $64,660 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $40,993 | None |
| Injection, denosumab, 1 mg | 27 | $35,842 | None |
| Return visit (30+ min) | 129 | $27,038 | $98 |
| New patient visit (45+ min) | 68 | $9,662 | $142 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 52 | $6,993 | $73 |
| Long return visit (40+ min) | 26 | $6,339 | $144 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $3,367 | $140 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | $3,329 | $101 |
| New patient visit (60+ min) | 14 | $2,815 | $201 |
| Telephone medical discussion with physician, 11-20 minutes | 27 | $2,737 | $74 |
| Short return visit (20+ min) | 18 | $1,462 | $66 |
| Injection of drug or substance under skin or into muscle | 51 | $1,436 | $14 |
| Aspiration and/or injection of fluid from large joint | 14 | $1,147 | $60 |
| Injection into tendon or ligament | 11 | $942 | $50 |
| Aspiration and/or injection of fluid from small joint | 13 | $719 | $42 |
| Administration of chemotherapy into vein, each additional hour | 12 | $693 | $32 |
| Injection, zoledronic acid, 1 mg | 16 | $655 | None |
| Injection, methylprednisolone acetate, 40 mg | 39 | $305 | None |
2019: 12 services
| Return visit (30+ min) | 130 | $31,554 | $98 |
| Injection, denosumab, 1 mg | 21 | $28,390 | None |
| New patient visit (45+ min) | 129 | $18,551 | $144 |
| Short return visit (20+ min) | 32 | $2,856 | $71 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 21 | $1,937 | $69 |
| Aspiration and/or injection of fluid from small joint | 16 | $1,339 | $48 |
| Injection of drug or substance under skin or into muscle | 34 | $1,095 | $15 |
| Aspiration and/or injection of fluid from large joint | 16 | $1,078 | $57 |
| Influenza vaccine split virus, preservative free | 16 | $878 | $55 |
| Administration of influenza virus vaccine | 16 | $328 | $21 |
| Injection, methylprednisolone acetate, 40 mg | 32 | $228 | None |
| Injection, methylprednisolone acetate, 20 mg | 14 | $52 | None |
2018: 6 services
| Injection, denosumab, 1 mg | 15 | $13,004 | None |
| New patient visit (45+ min) | 63 | $9,647 | $153 |
| Return visit (30+ min) | 69 | $9,264 | $102 |
| Short return visit (20+ min) | 16 | $1,318 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $1,047 | $75 |
| Injection of drug or substance under skin or into muscle | 23 | $533 | $20 |
2017: 8 services
| Injection, infliximab, excludes biosimilar, 10 mg | 22 | $330,932 | None |
| Return visit (30+ min) | 170 | $30,277 | $78 |
| Administration of chemotherapy into vein, 1 hour or less | 22 | $10,724 | $126 |
| New patient visit (45+ min) | 40 | $4,727 | $118 |
| Short return visit (20+ min) | 43 | $2,880 | $54 |
| Administration of chemotherapy into vein, each additional hour | 22 | $2,113 | $25 |
| New patient visit (30+ min) | 16 | $1,171 | $73 |
| Aspiration and/or injection of fluid from large joint | 17 | $1,006 | $42 |
2016: 8 services
| Injection, infliximab, excludes biosimilar, 10 mg | 30 | $565,450 | None |
| Return visit (30+ min) | 165 | $45,331 | $85 |
| Administration of chemotherapy into vein, 1 hour or less | 30 | $20,493 | $123 |
| New patient visit (45+ min) | 65 | $7,720 | $119 |
| Short return visit (20+ min) | 71 | $5,798 | $56 |
| New patient visit (30+ min) | 56 | $4,522 | $81 |
| Administration of chemotherapy into vein, each additional hour | 30 | $4,127 | $25 |
| Aspiration and/or injection of fluid from large joint | 21 | $1,597 | $48 |
2015: 7 services
| Injection, infliximab, excludes biosimilar, 10 mg | 26 | $194,728 | None |
| New patient visit (45+ min) | 128 | $17,086 | $133 |
| Return visit (30+ min) | 106 | $17,015 | $90 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $6,935 | $122 |
| New patient visit (30+ min) | 27 | $2,420 | $90 |
| Short return visit (20+ min) | 21 | $1,771 | $57 |
| Administration of chemotherapy into vein, each additional hour | 26 | $1,470 | $25 |
2014: 4 services
| New patient visit (45+ min) | 22 | $3,094 | $141 |
| Short return visit (20+ min) | 16 | $1,974 | $60 |
| Return visit (30+ min) | 17 | $1,839 | $74 |
| New patient visit (30+ min) | 14 | $1,275 | $91 |
2013: 5 services
| Return visit (30+ min) | 44 | $5,988 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,287 | $59 |
| Short return visit (20+ min) | 25 | $2,100 | $55 |
| New patient visit (45+ min) | 15 | $1,535 | $102 |
| Aspiration and/or injection of fluid from large joint | 12 | $1,250 | $52 |
Drugs they prescribed that Part D paid
$870,076
Pharmacies billed $870,076 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 6% of their Part D prescriptions (77 of 1,243) in 2024. Above the middle of the specialty; the typical rheumatology clinician is at 3%.
1,080 generic and 163 brand-name prescriptions · $870,076 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cosentyx Sensoready | 16 | $119,586 | $7,474 |
| Enbrel Sureclick | 13 | $95,772 | $7,367 |
| Benlysta | 13 | $62,969 | $4,844 |
| Teriparatide | 27 | $56,217 | $2,082 |
| Tymlos | 11 | $28,864 | $2,624 |
See all 28 drugs
| Cosentyx Sensoready | 16 | $119,586 | $7,474 |
| Enbrel Sureclick | 13 | $95,772 | $7,367 |
| Benlysta | 13 | $62,969 | $4,844 |
| Teriparatide | 27 | $56,217 | $2,082 |
| Tymlos | 11 | $28,864 | $2,624 |
| Celecoxib | 67 | $6,188 | $92 |
| Methotrexate | 113 | $4,739 | $42 |
| Hydroxychloroquine Sulfate | 64 | $3,929 | $61 |
| Mycophenolate Mofetil | 14 | $3,226 | $230 |
| Hydrocodone-Acetaminophen | 47 | $3,047 | $65 |
| Leflunomide | 42 | $2,627 | $63 |
| Gabapentin | 81 | $2,099 | $26 |
| Colchicine | 26 | $2,096 | $81 |
| Febuxostat | 12 | $1,578 | $132 |
| Famotidine | 67 | $1,482 | $22 |
| Sulfasalazine Dr | 16 | $1,184 | $74 |
| Prednisone | 100 | $1,033 | $10 |
| Alendronate | 100 | $806 | $8 |
| Allopurinol | 57 | $677 | $12 |
| Duloxetine | 28 | $654 | $23 |
| Pregabalin | 23 | $600 | $26 |
| Omeprazole | 30 | $581 | $19 |
| Ibandronate | 11 | $371 | $34 |
| Folic Acid | 14 | $358 | $26 |
| Methylprednisolone | 20 | $264 | $13 |
| Naproxen | 28 | $247 | $9 |
| Meloxicam | 23 | $88 | $4 |
| Tramadol | 16 | $77 | $5 |
Year by year
| 2024 | 1,243 | 287 | 6% (77) | 13% | $870,076 |
| 2023 | 1,268 | 277 | 6% (77) | None | $674,701 |
| 2022 | 1,171 | 238 | 6% (73) | None | $618,017 |
| 2021 | 934 | 194 | 9% (80) | None | $361,866 |
| 2020 | 813 | 146 | 6% (50) | None | $139,530 |
| 2019 | 732 | 185 | 6% (44) | None | $123,213 |
| 2018 | 509 | 216 | 8% (41) | None | $135,859 |
| 2017 | 2,169 | 286 | 9% (186) | None | $762,608 |
| 2016 | 3,312 | 329 | 8% (249) | 25% | $1,153,701 |
| 2015 | 970 | 210 | 7% (71) | 24% | $237,765 |
| 2014 | 778 | 185 | 9% (71) | None | $116,003 |
| 2013 | 2,371 | 346 | 17% (402) | 19% | $211,612 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 28 drugs
| Forteo | 35 | $152,352 | $4,353 |
| Enbrel Mini | 12 | $91,359 | $7,613 |
| Cosentyx Sensoready | 13 | $90,755 | $6,981 |
| Orencia Clickject | 13 | $75,435 | $5,803 |
| Benlysta | 11 | $54,282 | $4,935 |
| Methotrexate | 116 | $6,157 | $53 |
| Celecoxib | 57 | $5,582 | $98 |
| Hydroxychloroquine Sulfate | 81 | $5,575 | $69 |
| Colchicine | 24 | $4,203 | $175 |
| Febuxostat | 22 | $3,376 | $153 |
| Leflunomide | 38 | $2,788 | $73 |
| Hydrocodone-Acetaminophen | 47 | $2,339 | $50 |
| Famotidine | 72 | $1,894 | $26 |
| Pregabalin | 23 | $1,850 | $80 |
| Prednisone | 107 | $1,359 | $13 |
| Sulfasalazine Dr | 13 | $1,237 | $95 |
| Alendronate | 81 | $1,209 | $15 |
| Gabapentin | 76 | $1,191 | $16 |
| Ibandronate | 17 | $1,037 | $61 |
| Duloxetine | 33 | $1,030 | $31 |
| Allopurinol | 50 | $907 | $18 |
| Omeprazole | 40 | $657 | $16 |
| Meloxicam | 11 | $258 | $23 |
| Naproxen | 26 | $226 | $9 |
| Methylprednisolone | 17 | $194 | $11 |
| Tramadol | 15 | $68 | $5 |
| Folic Acid | 20 | $60 | $3 |
| Amlodipine Besylate | 12 | $40 | $3 |
2022: 25 drugs
| Forteo | 28 | $119,610 | $4,272 |
| Enbrel Mini | 13 | $91,157 | $7,012 |
| Methotrexate | 116 | $6,735 | $58 |
| Hydroxychloroquine Sulfate | 76 | $5,563 | $73 |
| Colchicine | 22 | $3,186 | $145 |
| Leflunomide | 25 | $3,048 | $122 |
| Hydrocodone-Acetaminophen | 41 | $2,822 | $69 |
| Celecoxib | 50 | $2,256 | $45 |
| Febuxostat | 11 | $2,037 | $185 |
| Pregabalin | 26 | $1,965 | $76 |
| Prednisone | 132 | $1,729 | $13 |
| Gabapentin | 75 | $1,588 | $21 |
| Alendronate | 68 | $942 | $14 |
| Famotidine | 50 | $924 | $18 |
| Duloxetine | 33 | $895 | $27 |
| Ibandronate | 15 | $808 | $54 |
| Diclofenac | 15 | $777 | $52 |
| Omeprazole | 46 | $630 | $14 |
| Leucovorin | 11 | $566 | $51 |
| Allopurinol | 34 | $563 | $17 |
| Baclofen | 15 | $375 | $25 |
| Methylprednisolone | 16 | $237 | $15 |
| Meloxicam | 18 | $181 | $10 |
| Tramadol | 18 | $99 | $5 |
| Folic Acid | 11 | $66 | $6 |
2021: 25 drugs
| Benlysta | 14 | $59,667 | $4,262 |
| Forteo | 14 | $57,695 | $4,121 |
| Posaconazole | 12 | $54,483 | $4,540 |
| Atovaquone | 11 | $15,160 | $1,378 |
| Methotrexate | 75 | $3,831 | $51 |
| Febuxostat | 18 | $3,516 | $195 |
| Colchicine | 15 | $3,075 | $205 |
| Hydroxychloroquine Sulfate | 40 | $2,931 | $73 |
| Leflunomide | 14 | $2,185 | $156 |
| Diclofenac | 25 | $2,003 | $80 |
| Prednisone | 105 | $1,818 | $17 |
| Celecoxib | 30 | $1,574 | $52 |
| Hydrocodone-Acetaminophen | 44 | $1,498 | $34 |
| Gabapentin | 42 | $1,195 | $28 |
| Pregabalin | 19 | $1,168 | $61 |
| Alendronate | 73 | $773 | $11 |
| Duloxetine | 25 | $588 | $24 |
| Allopurinol | 23 | $554 | $24 |
| Sulfasalazine | 11 | $463 | $42 |
| Famotidine | 32 | $461 | $14 |
| Sulfasalazine Dr | 11 | $453 | $41 |
| Omeprazole | 33 | $303 | $9 |
| Methylprednisolone | 17 | $207 | $12 |
| Tramadol | 29 | $171 | $6 |
| Meloxicam | 28 | $117 | $4 |
2020: 21 drugs
| Otrexup | 13 | $8,317 | $640 |
| Hydroxychloroquine Sulfate | 64 | $6,218 | $97 |
| Febuxostat | 16 | $5,160 | $322 |
| Methotrexate | 66 | $4,232 | $64 |
| Colchicine | 16 | $3,949 | $247 |
| Leflunomide | 15 | $1,834 | $122 |
| Diclofenac | 40 | $1,705 | $43 |
| Prednisone | 106 | $1,293 | $12 |
| Celecoxib | 24 | $869 | $36 |
| Mycophenolate Mofetil | 12 | $861 | $72 |
| Alendronate | 49 | $737 | $15 |
| Gabapentin | 42 | $588 | $14 |
| Allopurinol | 34 | $548 | $16 |
| Sulfasalazine Dr | 11 | $434 | $39 |
| Hydrocodone-Acetaminophen | 22 | $365 | $17 |
| Omeprazole | 34 | $347 | $10 |
| Famotidine | 23 | $235 | $10 |
| Cyclobenzaprine | 11 | $134 | $12 |
| Methylprednisolone | 12 | $119 | $10 |
| Sulfamethoxazole-Trimethoprim | 18 | $103 | $6 |
| Tramadol | 25 | $103 | $4 |
2019: 17 drugs
| Hydroxychloroquine Sulfate | 62 | $5,151 | $83 |
| Methotrexate | 80 | $3,364 | $42 |
| Colchicine | 18 | $2,801 | $156 |
| Prednisone | 111 | $1,574 | $14 |
| Pilocarpine | 13 | $1,353 | $104 |
| Diclofenac | 28 | $1,331 | $48 |
| Celecoxib | 21 | $902 | $43 |
| Nifedipine Er | 16 | $639 | $40 |
| Gabapentin | 26 | $618 | $24 |
| Omeprazole | 46 | $509 | $11 |
| Alendronate | 35 | $414 | $12 |
| Allopurinol | 28 | $356 | $13 |
| Hydrocodone-Acetaminophen | 17 | $266 | $16 |
| Naproxen | 11 | $247 | $22 |
| Tramadol | 22 | $106 | $5 |
| Meloxicam | 19 | $86 | $5 |
| Famotidine | 12 | $65 | $5 |
2018: 15 drugs
| Hydroxychloroquine Sulfate | 47 | $7,097 | $151 |
| Uloric | 14 | $6,358 | $454 |
| Leflunomide | 20 | $5,846 | $292 |
| Methotrexate | 44 | $3,210 | $73 |
| Colchicine | 12 | $2,082 | $173 |
| Celecoxib | 27 | $1,810 | $67 |
| Prednisone | 69 | $777 | $11 |
| Gabapentin | 29 | $699 | $24 |
| Hydrocodone-Acetaminophen | 11 | $430 | $39 |
| Alendronate | 30 | $387 | $13 |
| Leucovorin | 11 | $367 | $33 |
| Tramadol | 22 | $167 | $8 |
| Methylprednisolone | 13 | $149 | $11 |
| Meloxicam | 15 | $86 | $6 |
| Omeprazole | 11 | $75 | $7 |
2017: 36 drugs
| Enbrel Sureclick | 34 | $169,684 | $4,991 |
| Humira | 26 | $148,612 | $5,716 |
| Enbrel | 11 | $78,197 | $7,109 |
| Orencia | 14 | $53,812 | $3,844 |
| Humira | 11 | $48,364 | $4,397 |
| Leflunomide | 191 | $42,795 | $224 |
| Forteo | 13 | $36,722 | $2,825 |
| Hydroxychloroquine Sulfate | 118 | $18,032 | $153 |
| Lyrica | 30 | $15,625 | $521 |
| Methotrexate | 250 | $14,602 | $58 |
| Uloric | 16 | $9,040 | $565 |
| Colchicine | 46 | $8,700 | $189 |
| Cevimeline | 21 | $5,494 | $262 |
| Prednisone | 248 | $3,229 | $13 |
| Risedronate | 19 | $3,105 | $163 |
| Celecoxib | 28 | $2,806 | $100 |
| Gabapentin | 98 | $2,685 | $27 |
| Colcrys | 12 | $2,640 | $220 |
| Sulfasalazine Dr | 39 | $1,883 | $48 |
| Azathioprine | 33 | $1,664 | $50 |
| Duloxetine | 40 | $1,464 | $37 |
| Omeprazole | 133 | $1,210 | $9 |
| Diclofenac | 30 | $998 | $33 |
| Alendronate | 138 | $989 | $7 |
| Tramadol | 117 | $947 | $8 |
| Allopurinol | 54 | $905 | $17 |
| Hydrocodone-Acetaminophen | 62 | $740 | $12 |
| Baclofen | 26 | $467 | $18 |
| Mycophenolate Mofetil | 12 | $394 | $33 |
| Sulfasalazine | 14 | $384 | $27 |
| Methylprednisolone | 19 | $275 | $14 |
| Meloxicam | 32 | $272 | $9 |
| Sulfamethoxazole-Trimethoprim | 16 | $257 | $16 |
| Naproxen | 18 | $132 | $7 |
| Pantoprazole | 14 | $96 | $7 |
| Leucovorin | 12 | $65 | $5 |
2016: 39 drugs
| Enbrel | 83 | $369,754 | $4,455 |
| Humira | 38 | $204,997 | $5,395 |
| Humira | 22 | $87,746 | $3,988 |
| Cimzia | 11 | $74,451 | $6,768 |
| Leflunomide | 266 | $53,854 | $202 |
| Orencia | 15 | $53,347 | $3,556 |
| Forteo | 21 | $51,990 | $2,476 |
| Xeljanz | 15 | $50,422 | $3,361 |
| Hydroxychloroquine Sulfate | 193 | $31,424 | $163 |
| Methotrexate | 458 | $25,483 | $56 |
| Lyrica | 41 | $16,874 | $412 |
| Colchicine | 63 | $11,545 | $183 |
| Uloric | 26 | $10,408 | $400 |
| Cevimeline | 21 | $5,938 | $283 |
| Colcrys | 22 | $5,769 | $262 |
| Celecoxib | 40 | $5,656 | $141 |
| Pilocarpine | 27 | $4,871 | $180 |
| Prednisone | 436 | $4,619 | $11 |
| Risedronate | 23 | $3,985 | $173 |
| Duloxetine | 39 | $3,299 | $85 |
| Ursodiol | 15 | $3,264 | $218 |
| Sulfasalazine Dr | 61 | $2,865 | $47 |
| Gabapentin | 95 | $2,698 | $28 |
| Omeprazole | 204 | $2,082 | $10 |
| Tramadol | 147 | $1,793 | $12 |
| Diclofenac | 41 | $1,534 | $37 |
| Hydrocodone-Acetaminophen | 76 | $1,413 | $19 |
| Allopurinol | 73 | $1,280 | $18 |
| Alendronate | 191 | $1,256 | $7 |
| Azathioprine | 20 | $1,192 | $60 |
| Sulfasalazine | 36 | $1,022 | $28 |
| Sulfamethoxazole-Trimethoprim | 28 | $781 | $28 |
| Meloxicam | 71 | $776 | $11 |
| Methylprednisolone | 40 | $747 | $19 |
| Naproxen | 51 | $479 | $9 |
| Baclofen | 26 | $306 | $12 |
| Pantoprazole | 12 | $171 | $14 |
| Ibuprofen | 19 | $157 | $8 |
| Tramadol Hcl Er | 11 | $151 | $14 |
2015: 21 drugs
| Enbrel | 20 | $70,920 | $3,546 |
| Leflunomide | 49 | $9,481 | $193 |
| Hydroxychloroquine Sulfate | 55 | $7,570 | $138 |
| Methotrexate | 94 | $6,061 | $64 |
| Colchicine | 21 | $5,555 | $265 |
| Lyrica | 17 | $5,212 | $307 |
| Colcrys | 12 | $3,597 | $300 |
| Uloric | 14 | $3,590 | $256 |
| Prednisone | 178 | $1,940 | $11 |
| Duloxetine | 11 | $896 | $81 |
| Sulfasalazine Dr | 17 | $643 | $38 |
| Tramadol | 53 | $547 | $10 |
| Gabapentin | 33 | $531 | $16 |
| Allopurinol | 23 | $502 | $22 |
| Hydrocodone-Acetaminophen | 17 | $417 | $25 |
| Methylprednisolone | 23 | $408 | $18 |
| Omeprazole | 66 | $363 | $6 |
| Alendronate | 61 | $295 | $5 |
| Sulfasalazine | 14 | $287 | $21 |
| Naproxen | 16 | $103 | $6 |
| Meloxicam | 12 | $70 | $6 |
2014: 17 drugs
| Forteo | 35 | $54,599 | $1,560 |
| Lyrica | 24 | $7,700 | $321 |
| Duloxetine | 29 | $5,835 | $201 |
| Methotrexate | 58 | $4,751 | $82 |
| Alendronate | 144 | $1,213 | $8 |
| Hydrocodone-Acetaminophen | 35 | $1,061 | $30 |
| Prednisone | 43 | $708 | $16 |
| Gabapentin | 39 | $680 | $17 |
| Omeprazole | 60 | $657 | $11 |
| Leflunomide | 20 | $574 | $29 |
| Voltaren | 12 | $504 | $42 |
| Hydroxychloroquine Sulfate | 37 | $503 | $14 |
| Tramadol | 32 | $336 | $11 |
| Allopurinol | 43 | $248 | $6 |
| Baclofen | 26 | $226 | $9 |
| Naproxen | 18 | $173 | $10 |
| Ibuprofen | 11 | $139 | $13 |
2013: 28 drugs
| Forteo | 42 | $56,209 | $1,338 |
| Enbrel | 12 | $28,892 | $2,408 |
| Humira | 11 | $25,302 | $2,300 |
| Lyrica | 77 | $17,126 | $222 |
| Cymbalta | 56 | $13,629 | $243 |
| Colcrys | 51 | $12,811 | $251 |
| Methotrexate | 173 | $12,037 | $70 |
| Gabapentin | 153 | $4,943 | $32 |
| Celebrex | 13 | $3,353 | $258 |
| Hydrocodone-Acetaminophen | 147 | $3,154 | $21 |
| Alendronate | 248 | $2,173 | $9 |
| Pilocarpine | 26 | $2,085 | $80 |
| Tramadol | 199 | $2,077 | $10 |
| Omeprazole | 157 | $1,890 | $12 |
| Sulfasalazine | 68 | $1,510 | $22 |
| Hydroxychloroquine Sulfate | 80 | $1,453 | $18 |
| Leflunomide | 41 | $1,140 | $28 |
| Naproxen | 95 | $994 | $10 |
| Prednisone | 95 | $943 | $10 |
| Voltaren | 23 | $905 | $39 |
| Acetaminophen-Codeine | 35 | $787 | $22 |
| Methylprednisolone | 29 | $700 | $24 |
| Baclofen | 108 | $692 | $6 |
| Ibuprofen | 60 | $566 | $9 |
| Allopurinol | 100 | $564 | $6 |
| Sulfazine | 15 | $314 | $21 |
| Azathioprine | 12 | $161 | $13 |
| Zolpidem | 12 | $60 | $5 |
Money from drug and device companies
$16 in 2025
| 2025 | 1 | 1 | None | $16 |
| 2023 | 2 | 2 | None | $215 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Uplizna | $16 | 1 payment
|
See the published payment
| Amgen | Meals · 2025-10-03 | Uplizna | $16 |
See earlier years (2023)
2023: $215
| Horizon Therapeutics plc | Krystexxa | $137 | 1 payment
|
| Abbvie | Rinvoq | $78 | 1 payment
|
Professional record
- NPI
- 1720263825
- Licence
- CA A100963California A100963: Current · expires 2027-05-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
- Mailing address
- 50 E Hamilton Ave Ste 200, Campbell, CA, 95008
- NPI first listed
- 2008-01-08
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 675 S Arroyo Pkwy, Pasadena, CA, 91105